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Abstract
Introduction: Neutrophil accumulation is a well-established feature of Alzheimer’s disease (AD) and has been linked
to cognitive impairment by modulating disease-relevant neuroinflammatory and vascular pathways. Neutrophils
express high levels of the oxidant-generating enzyme myeloperoxidase (MPO), however there has been controversy
regarding the cellular source and localisation of MPO in the AD brain.
Materials and methods: We used immunostaining and immunoassays to quantify the accumulation of neutrophils
in human AD tissue microarrays and in the brains of APP/PS1 mice. We also used multiplexed immunolabelling to
define the presence of NETs in AD.
Results: There was an increase in neutrophils in AD brains as well as in the murine APP/PS1 model of AD. Indeed,
MPO expression was almost exclusively confined to S100A8-positive neutrophils in both human AD and murine APP/
PS1 brains. The vascular localisation of neutrophils in both human AD and mouse models of AD was striking and
driven by enhanced neutrophil adhesion to small vessels. We also observed rare infiltrating neutrophils and deposits
of MPO around plaques. Citrullinated histone H3, a marker of neutrophil extracellular traps (NETs), was also detected
in human AD cases at these sites, indicating the presence of extracellular MPO in the vasculature. Finally, there was a
reduction in the endothelial glycocalyx in AD that may be responsible for non-productive neutrophil adhesion to the
vasculature.
Conclusion: Our report indicates that vascular changes may drive neutrophil adhesion and NETosis, and that
neutrophil-derived MPO may lead to vascular oxidative stress and be a relevant therapeutic target in AD.
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Background
Neutrophils are the most abundant circulating leukocyte,
and they play a critical role as first responders to inflammation [1]. However, there is now a growing appreciation for the role that neutrophils play in chronic diseases
[2]. Indeed, neutrophils may have differential roles in the
contexts of acute and chronic inflammation [2]. Most
evidence from acute inflammation suggests that they
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are beneficial, especially in containing infection, while in
chronic sterile inflammation evidence suggests that offtarget effects of neutrophil activation can contribute to
tissue damage [2].
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by the accumulation of amyloid
plaques and tangles of hyperphosphorylated tau [3].
Interestingly, AD has a chronic neuroinflammatory
component that drives neurodegeneration [4–6], and
cerebrovascular inflammation is important in recruiting peripheral immune cells in other neuroinflammatory
diseases [7, 8]. Neutrophil accumulation in AD has been
well documented [9–12], but recent reports also indicate
that neutrophils contribute to pathology and cognitive
impairment in AD [9, 11–13], consistent with the idea
that they play a deleterious role in chronic diseases [2].
Indeed, there is an amyloid-independent improvement
in cognition in mouse AD models when neutrophils are
depleted or when interactions between neutrophils and
cell adhesion molecules in blood vessels are blocked [9,
11, 12]. There have been reports of both neutrophil infiltration [10, 11] and vascular localisation [12, 13], and
recent studies have indicated that neutrophil plugging of
capillaries reduces cerebral blood flow in both the APP/
PS1 and 5XFAD models of AD to drive cognitive deficits [12, 13], although the localisation of neutrophils in
human Alzheimer brains has not been analysed in any
detail.
In order to infiltrate the brain, neutrophils must pass
across the blood brain barrier (BBB), formed by brain
endothelial cells. Under normal circumstances, circulating neutrophils flow through cerebral vessels. However,
following an injury, inflammation triggers the expression
of chemokines and adhesion molecules in cerebral vessels
that recruit and promote the attachment of neutrophils
to the vessel wall [14, 15]. Concurrently, the glycocalyx,
a proteoglycan structure that prevents the interaction
of surface molecules such as cell adhesion molecules,
collapses, facilitating neutrophil attachment [16]. Once
adhered to the vasculature, the interaction of endothelial membrane protrusions, containing multiple adhesion
molecules, facilitate the migration of immune cells into
the brain parenchyma [17].
The neutrophil oxidant-producing enzyme myeloperoxidase (MPO) has also been suggested to play a role
in AD [9, 12, 18–21]. Adoptive transfer of bone marrow from Mpo−/− to 5XFAD mice reduces neuroinflammation, indicating a role for MPO-derived oxidants in
AD-associated neuroinflammation [9]. While there is a
consensus that MPO abundance is increased in AD, there
are conflicting reports regarding its localisation and cellular source. MPO has been reported to localise to amyloid plaques [18, 20] and tau tangles [19], while the brain
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cells that have been reported to produce MPO include
neurons [19], astrocytes [20], and microglia [19], as well
as neutrophils [11]. The localisation and source of MPO
has a profound impact on the targets of MPO-derived
oxidants [22], especially because the major oxidant produced, hypochlorous acid (HOCl), is extremely reactive
and has a limited diffusion radius [23].
In neutrophils, MPO is contained within cytoplasmic granules, and degranulation must occur before the
enzyme is fully active. One way of enabling MPO release
is the formation of neutrophil extracellular traps (NETs)
in which mixing of chromatin and granule contents
occurs, before the NET is expelled [24]. Once released,
NETs are powerful activators of the immune response,
forming a DNA–protein matrix decorated with damage-associated molecular patterns such as S100 proteins
[25–27]. While infectious agents trigger NET formation
[28], they have also been reported in sterile inflammatory
diseases, including atherosclerosis and gall-stone formation [24, 29, 30]. There have been preliminary reports of
NETosis in AD [11], however the abundance and localisation of the NETs have not yet been characterised.
We set out to investigate the accumulation and localisation of neutrophils in AD, as well as the source and distribution of MPO. We confirmed that there is neutrophil
accumulation in AD, and demonstrated using a panel of
antibodies that MPO was almost exclusively localised
with other neutrophil markers. Strikingly, neutrophils
accumulated throughout the vasculature in the AD brain,
but only limited infiltration observed. We also observed
rare deposits of MPO outside the vasculature, which
were associated with plaques. To test whether plaqueassociated MPO was present as NETs, we used a panel
of antibodies to stain for potential NETosis, and while we
did observe specific NET labelling these were only found
in the vasculature. We also observed that there was a loss
of endothelial glycocalyx staining in the AD vasculature,
which may drive enhanced neutrophil-vascular interactions in AD.

Materials and methods
Human tissue

All post-mortem human brain tissue used in this study
was obtained from the Neurological Foundation of New
Zealand Human Brain Bank in the Centre for Brain
Research, University of Auckland. All protocols in this
study were approved by the University of Auckland
Human Participants Ethics Committee (2008/279 and
011,654), and all families provided informed consent. All
cases were examined by an independent neuropathologist and were classified based on neurological abnormalities, or lack thereof in neurologically normal control
cases (Additional file 1: Table S1). Tissue microarrays
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of AD and control tissue were generated from paraffinembedded blocks as described previously [31, 32].
Animal models
APP/PS1 transgenic mice

APP/PS1 transgenic mice on a C57BL/6 J background were bred at Otago University, New Zealand,
from stock imported from the Jackson Laboratory
((APPswe,PSEN1dE9)85Dbo, MMRRC stock No: 34832JAX). Non-litter matched transgenic (n = 12) and wildtype (n = 12) male mice were obtained by breeding
hemizygous males with wild-type females. Animals were
single group-housed in standard caging on a 12-h light/
dark cycle, and food and water were available ad libitum.
Ethical approval for the mouse work was obtained from
the University of Otago Animal Ethics Committee (AUP19–82). Mice were euthanised by transcardial perfusion
with saline followed by 4% paraformaldehyde (PFA) at 4
and 12 months of age, and tissue fixed by perfusion in 4%
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB)
for 1 day, followed by 30% sucrose in PB for 2 days. In
all experiments, male mice were used. Brains were stored
in optimal cooling temperature mounting medium and
were sectioned in the sagittal plane (40 μm thickness).
Sections were stored in cryoprotectant solution containing 30% sucrose and 30% ethylene glycol in PB at – 20 °C
for later use.
Stroke

All procedures were performed in accordance with the
guidelines on the care and use of laboratory animals set
out by the University of Otago, Animal Research Committee (AUP-19–160). Focal stroke was induced by photothrombosis in adult male C57BL/6 J mice (3–4 months,
27–30 g) as previously described [33–35]. Under isoflurane anaesthesia (4% induction, 2–2.5% maintenance in
O2) mice were placed in a stereotactic frame (9000RR-BU, KOPF; CA, USA), and buprenorphine hydrochloride
(0.1 mL of a 0.5 mg/kg solution, Temgesic.) was administered subcutaneously as pre-emptive post-surgical
pain relief. Following sterilisation of the skin using chlorhexidine (30% in 70% ethanol, Hibitane), the skull was
exposed through a midline incision, cleared of connective
tissue and dried. A cold light source (KL1500 LCD, Zeiss,
Auckland, New Zealand) attached to a 40 × objective
providing a 2-mm diameter illumination was positioned
1.5 mm lateral from bregma. Then, 0.2 mL of Rose Bengal
(Sigma-Aldrich; 10 mg/mL in sterile saline) was administered i.p.. After 5 min, the brain was illuminated through
the exposed intact skull for 15 min, while keeping body
temperature at 37 °C using a heating pad. The skin was
glued, and animals left in a cage placed on a heating pad
until they had recovered before being returned to their
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home-cage. Sham surgery was performed in the exact
same way, except saline was injected instead of Rose Bengal. Mice were housed in groups of three to five under
standard conditions in individually ventilated cages (IVC:
Tecniplast: maintained at 21 °C ± 2 °C and humidity of
50% ± 10%), on a reverse 12 h light/dark cycle (white
lights off from 07:00–19:00) with ad libitum access to
food and water. Following stroke or sham surgery, animals were euthanised 1-, 3-, and 14-days post stroke
(n = 6), with sham controls taken at 1 and 14 days (n = 3).
Brains were fixed and embedded in paraffin blocks for
sectioning.
Immunohistochemistry
Paraffin‑embedded tissue

Formalin-fixed paraffin embedded sections (7 μm thickness) were dewaxed in xylene for at least 1 h, followed
by rehydration through an alcohol series. Heat-induced
epitope retrieval was performed in tris–EDTA (10 mM
tris–HCl, 1 mM EDTA, 0.05% Tween-20 (v/v), pH 9.0)
using a pressure cooker. For the detection of amyloid-β
and phospho-tau, antigen retrieval was performed in 80%
formic acid for 3 min. Once sections were cooled and
washed, they were blocked in 10% normal donkey serum
(NDS) for 1 h. Primary antibodies, diluted appropriately
(in 1% NDS in phosphate-buffered saline (PBS)), were
added to sections overnight at 4 °C (antibody details in
table S2). Primaries were removed, and sections washed
in PBS, before appropriate species-specific secondary antibodies with Hoechst 33,342 (50 μg/mL; ThermoFisher, OR, USA) or DAPI (500 ng/mL; ThermoFisher)
were added (in 1% NDS in PBS) for 4 h at room temperature. Coverslips were mounted onto sections with
Prolong Gold antifade mountant (ThermoFisher) before
imaging. Large human sections were imaged on a Nikon
Eclipse Ni microscope (20 × objective, NA 0.50; Nikon,
Japan) with large regions acquired by tiling. Mouse sections were acquired using a Zeiss Axio Imager (20X
objective, NA 0.5; Carl Zeiss, Germany) with Apotomebased deconvolution.
Massively multiplexed immunostaining

Using a protocol adapted from Maric et al. [36] and Murray et al. [37], paraffin-embedded tissue microarray sections of AD and normal middle temporal gyrus were
processed as above. Imaging was carried out with an
automated fluorescence microscope (Zeiss Z2 Axioimager) equipped with MetaSystems VSlide slide scanner
(MetaSystems) running MetaFer (V 3.12.1) with a 20 × air
objective (0.9 NA). This microscope is equipped with
6 custom excitation/dichroic/emission filter sets optimised for spectral separation of compatible fluorophores
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as previously described (Maric et al. [36]). Antibodies
were then stripped from sections with the addition of 5X
NewBlot™ Nitro Stripping Buffer (Li-Cor, NE, USA) for
10 min at room temperature. Sections were then washed
in PBS, epitope retrieval performed where necessary, and
a subsequent round of immunostaining and imaging performed as above. This was completed over four rounds.
Alignment of images from all four rounds was performed
using a custom Python script [38]. We confirmed the
effectiveness of stripping at removing previous antibodies in Additional file 1: Figure S5.
Neutrophil isolation

Venous blood was collected from healthy donors with
informed consent under the ethical approval of the
Southern Health and Disability Ethics Committee (Wellington, New Zealand [URA/06/12/083]). Neutrophils
were isolated as previously described [39]. Briefly, dextran (1% (w/v)) sedimentation was followed by Ficoll
density centrifugation, then hypotonic lysis to remove
remaining red blood cells. Granulocytes were suspended
in RPMI-1640 (Gibco, CA, USA) containing 2% FBS plus
10 mM HEPES. Purity was assessed by flow cytometry,
and cultures were routinely > 98% pure. Where relevant,
serum was obtained from blood collected without anticoagulant and left to clot at room temperature. The clot was
pelleted (1200×g; 2 min) and the serum was collected
and stored on ice until required.
Amyloid‑β preparation

Lyophilised Aβ1-42 (H1368, Bachem) peptide was resuspended in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP;
105,228, Sigma) to 1 mM through the rubber septum
using a 2.5 mL glass Hamilton syringe with a Teflon
plunger and sharp needle and allowed to sit at room temperature for 30 min. Aβ1-42-HFIP solution was aliquoted
into single-use lo-bind Eppendorf tubes and allowed to
sit overnight in a fume hood to evaporate HFIP. To ensure
complete removal, tubes were transferred to a SpeedVac
and dried for 1 h at room temperature. The resulting peptide films were stored at – 20 °C until use. To generate
a monomeric preparation of Aβ1-42 the peptide film was
allowed to come to room temperature, diluted to 5 mM
in DMSO and sonicated for 10 min in a bath sonicator at
room temperature. Aβ1-42 was further diluted in phenolred free DMEM (Gibco) to 100 μM and used immediately
for the monomeric preparation. To generate oligomers,
the monomeric preparation method was used, however,
the resulting Aβ1-42 preparation was incubated at 4 °C
for 24 h prior to use. To generate fibrils, the Aβ1-42 solution was diluted to 100 μM in 10 mM HCl and incubated
at 37 °C for 24 h prior to use. To generate aggregates,
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Aβ1-42 was resuspended in sterile water at 500 µM, vortexed thoroughly, and stored in aliquots at – 20 °C. In all
instances Aβ1-42 was diluted to a final concentration of
1 µM in culture media.
ELISA
MPO

Myeloperoxidase abundance and activity was measured
in clarified brain tissue lysates from the entorhinal cortex. Brain samples that had been snap frozen at -80 °C
were placed in lysis buffer (25 mM Tris–HCl pH 7.5,
150 mM NaCl, 50 mM NaF, 0.5 mM EDTA pH 8, 0.5%
Triton-X 100™, 5 mM β-glycerophosphate, with fresh
1 mM DTT, 1 mM PMSF, 1 mM Na3VO4) with 1 mm
stainless steel beads and homogenised with a bead beater.
The lysate was then spun at 14 000 × g for 20 min, and
the supernatant containing soluble protein taken. Samples were normalised to protein content in diluent (1%
(w/v) bovine serum albumin (BSA) in PBS with 0.05%
Tween-20 (v/v)). A high-binding 96 well plate was then
coated in a mouse anti-MPO capture antibody (1:500 in
PBS; clone 4A4, ThermoFisher) overnight at 4 °C. The following day, wells were blocked in diluent for 1 h at room
temperature. Samples were added alongside an 8-point
standard curve (0.7 – 50 ng/mL) of purified MPO, and
left for 1 h at room temperature. AmplexRed assay buffer
(50 μM AmplexRed, ThermoFisher; in 50 mM phosphate
buffer with 50 mM NaBr and 20 μM H2O2) was added for
15 min, and fluorescence (ex 530 nm, Em 590 nm) was
measured on a Synergy Neo2 HTS plate reader (BioTek,
VT, USA). A rabbit polyclonal antibody to MPO (1:800
in diluent) was then added overnight at 4 °C. Biotinylated
goat anti-rabbit secondary antibody (1:2000; Sigma, MO,
USA) was added for 1 h at 37 °C, followed by ExtrAvidin alkaline phosphatase (1:1000; Sigma) for 1 h at room
temperature. The alkaline phosphatase activity of samples
was then measured from the conversion of p-nitrophenyl
phosphate, with absorbance measured at 405 nm using a
VarioSkan™ LUX microplate reader (ThermoFisher).
Calprotectin

The abundance of calprotectin was measured in samples
using the commercially available CALPRO ELISA kit
(Svar, Sweden) as per manufacturer’s instructions.
Sytox green NETosis assay

Acutely isolated neutrophils were seeded in RPMI-1640
with 2% FBS and 5 μM Sytox Green (ThermoFisher) at
100 000 cells/well in a 96 well plate. A control where
Sytox Green was absent was included for background
subtraction. Neutrophils stimulated with phorbol
12-myristate 13-acetate (20 nM, PMA; Sigma) were
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used as a positive control. Neutrophils were treated
with amyloid-β1-42 (1 μM, Aβ1-42), with 10% (v/v) autologous donor serum, the monoclonal antibody against
Aβ1-42 4G8 (10 ng/mL), or vehicle (0.01% DMSO). Fluorescence (ex 460 nm, Em 516 nm) was measured every
5 min on a Synergy Neo2 HTS plate reader (BioTek, VT,
USA).

MPO colocalisation/association

Thioflavin T assay

A low all-vessel threshold was performed as above and
dilated, then the MPO image masked by this. MPO-positive objects were then identified in the masked area (vasculature) and the unmasked area (parenchyma).

Freshly prepared Aβ1-42 species or vehicles were added to
PBS containing 20 mM thioflavin T (ThT). Samples were
left at 37 °C for 1 h, then fluorescence (ex 440 nm, em
492 nm) measured with a VarioSkan™ LUX microplate
reader.
Negative‑stain transmission electron microscopy

Copper grids with 300 meshes coated with formvar/carbon film (ProSciTech, Australia) were floated on a 5 μl
drop of a 50 µM Aβ1-42 protein sample and incubated
for 60 s. Grids were washed once with water, and then
floated on 5 μl of uranyl acetate solution (2% w/v) for
30 s. Micrographs were taken on a Philips CM200 200 kV
transmission electron microscope equipped with a Gatan
digital camera.
Image analysis

All automated image analysis was performed on CellProfiler (v4.0.7) using custom pipelines. The experimenters were blinded to the genotype and pathology of the
patients in all cases.
Neutrophil and NET abundance

Neutrophils were thresholded based on intense staining
for MPO and S100A8 following rolling ball background
subtraction and smoothing. Large objects were excluded.
NETs were identified as being positive for CitH3, S100A8,
and MPO. A lectin mask was used to determine their
localisation as vascular.
Lectin intensity

A low all-vessel threshold was performed following
rolling ball background subtraction to include mid
and low intensity vessels. Alternatively, collagen IVpositive vessels were identified with a high threshold.
Large and small objects were filtered out. The size of
objects was measured and segregated into ‘large’ and
‘small’ vessels based on the minor axis length cut-off of
12 μm (lectin) or 15 μm (collagen IV). The mean intensity within the large vessel and small vessel objects was
then measured.

MPO, S100A8, amyloid-β, and pTau positive structures
were thresholded following rolling ball background subtraction. Objects that were touching were considered
colocalised/associated.
Vascular vs extravascular MPO

Yang et al. database [40]

Single-nuclear RNA-seq counts from the human AD vasculature were obtained from https://twc-stanford.shiny
apps.io/human_bbb/.
Data analysis

Data were analysed with GraphPad Prism (v 9.01). Data
from larger TMA cohorts are presented as box-andwhisker, with the range, interquartile range, and median
presented. Where outlier values were detected (> 2
SD outside the mean), staining quality was inspected
to ensure the validity of results and if artefacts were
detected, the outlier was removed. Otherwise, the
value was included. All other data are presented as
mean ± standard error of mean. Appropriate statistical
tests were carried out, following a test of the normality
of data. Briefly, t-tests were performed where there were
two groups, and two-way ANOVA where there were two
factors. Multiple comparisons were performed with Tukey’s post-hoc test.

Results
Neutrophils accumulate in the human AD brain and APP/
PS1 mouse model of AD

We initially used tissue microarrays to measure the
accumulation of neutrophils in the human AD brain
using a range of markers including three antibodies against MPO, as well as antibodies against CD66B,
and S100A8. For all of these markers, small spherical
cells were observed, with little apparently glial or neuronal immunoreactivity, indicating that, as expected,
they were detecting neutrophils (Fig. 1a-e). Additionally, cells stained for these antibodies had polymorphic nuclei, indicating that the cells they stained
were indeed neutrophils (Additional file 1: Fig. S1).
We found that there was a consistent increase in the
abundance of these neutrophils within AD brains, as
measured by all MPO antibodies, as well as antibodies
against S100A8 and CD66B (Fig. 1a-e). Although other
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Fig. 1 Cerebral accumulation of neutrophils in APP/PS1 mice and human Alzheimer’s disease. Human brain tissue microarrays (N = 21–46 per
condition) of middle temporal gyrus were stained for neutrophil markers a MPO (A0398), b MPO (ab1191060), c MPO (AF3667), d CD66B, and e
S100A8. Scale = 250 μm, inset = 25 μm. P-values represent results of an two-tailed Student’s T-test.Brain sections from APP/PS1 or wild type mice
were taken at 4 and 12 months, and stained for the neutrophil markers S100A8 and MPO. f Representative images and g analysis of neutrophil
abundance in mouse brains. Scale = 100 μm. P-values represent results of a two-way ANOVA. The abundance and activity of neutrophil markers h, i
MPO and j calprotectin in human brain tissue lysates was measured by ELISA (N = 7 – 13 per condition). P-values represent results of an two-tailed
Student’s T-test

studies have detected S100A8 in other cell types [41],
in our hands it was a reliable marker for neutrophils.
In order to stain murine AD model brains, we tested a
range of antibodies but found that only AF3667 gave
specific signal in positive control stroke tissue (Additional file 1: Fig. S1). Analysis of neutrophil density by

sex, age, and post-mortem delay revealed neutrophil
accumulation was independent of these covariates,
although we observed somewhat greater variability in
males (Additional file 1: Fig. S2). We immunolabelled
MPO and S100A8 in the APP/PS1 mouse model, which
has previously been shown to have cerebral neutrophil
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accumulation, and we observed an increase in neutrophil abundance in the cortex of both 4 and 12-monthold mice, although this was less striking than in human
specimens (Fig. 1f, g). Regional analysis of mouse brains
indicated that this effect was strongest in the cortex and
hippocampus, although similar trends were observed in
brainstem and cerebellum (Additional file 1: Fig. S3).
Cortical and hippocampal densities were similar, and
neutrophil accumulation in these regions was therefore
quantified together. Finally, we observed an increase in
the abundance of neutrophil markers calprotectin, of
which S100A8 is a subunit, and MPO in AD brains by
ELISA (Fig. 1h-j).
MPO accumulation in the AD brain is driven by an increase
in vascular neutrophils

Because we mainly observed neutrophil-like MPO staining in brain tissue, we wanted to determine if neutrophil
abundance was the major factor driving the increase in
MPO found in AD [18–20]. We therefore used alternative neutrophil markers calprotectin and S100A8 in
immunostaining and ELISA, and found that these were
positively correlated with MPO abundance (Fig. 2a, b).
Indeed, in immunolabelling experiments at least 97%
of MPO-positive cells were co-labelled with S100A8
(Fig. 2c). Previous reports have suggested that neutrophil accumulation in mouse AD models occurs primarily in the vasculature [12], and we therefore wished to
determine the localisation of neutrophils relative to
blood vessels. We used tissue microarrays to measure
MPO localisation within the human AD brain and found
that neutrophils were present in higher numbers in the
human AD vasculature (Fig. 2d, e). Interestingly, when we
compared the localisation of neutrophils by vessel segment, we observed that there were increases in both large
and small vessels, however the magnitude of increase was
greater in small vessels (< 12 μm diameter; Fig. 2d, e). In
both control and AD brains we found that the majority
of MPO labelling was contained in blood vessels (Fig. 2f ).
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Interestingly, we also observed the presence of the BBB
leakage product hemoglobin in close proximity to neutrophils found within blood vessels (Fig. 2g). In mouse
AD model brains, we found a similarly striking vascular localisation of neutrophils in APP/PS1 mouse brains
(Fig. 2h), as has been described previously [12].
Although the majority of neutrophils were found
in the vasculature, we did observe rare extravascular
CD66B-positive neutrophils indicating that infiltration
does occur, albeit at a low rate (Fig. 3a, b). Furthermore,
we observed sporadic deposition of MPO localised to
amyloid plaques and tau tangles (Fig. 3a-d). Indeed,
approximately half of the extravascular MPO-positive
structures were localised to plaques, and a quarter to
tangles (Fig. 3a, e). We observed significant correlations
between both amyloid and tau deposition and MPO
accumulation, although this was stronger for amyloid
than tau (Fig. 3f, g).
NETosis occurs in the AD vasculature

The formation of NETs is an important neutrophil effector function, and has been linked to vascular remodelling
in the retina as well as stroke and traumatic brain injury
[42–44]. We initially hypothesised that NETs would be
present in the AD vasculature and MPO deposits around
plaques in the brain. We used massively multiplexed
immunolabelling of brains to stain a panel of pathological (Aβ, tau, NeuN), inflammatory (Iba1, L-ferritin, HLADR, GFAP), vascular (Lectin, Collagen IV, hemoglobin),
and neutrophil markers (MPO, S100A8), alongside the
specific NET marker CitH3 to categorically define NETs
(Fig. 4a). We confirmed the specificity of the CitH3 antibody in brain tissue, detecting NETs in a murine model
of stroke (Additional file 1: Fig. S1). We observed the
presence of CitH3 exclusively localised to neutrophil
markers, however only a sub-population of neutrophils was detected, indicating that it was indeed labelling NETs (Fig. 4b). We hypothesised that, analogous to
their response to other large aggregated structures such

(See figure on next page.)
Fig. 2 MPO accumulation in Alzheimer’s disease and APP/PS1 mice is driven by neutrophil accumulation. a ELISA was performed in neurologically
normal and Alzheimer’s disease brains for the myeloperoxidase and calprotectin (S100A8/9 heterodimer). N = 7–13. P-values represent results of a
Pearson’s correlation test. b FFPE-embedded human brain sections from the middle temporal gyrus (N = 3–6 per condition) were immunostained
for MPO and S100A8. Correlation between MPO and S100A8 positive cells in independent sections. Values represent results of a Pearson’s
correlation test. c Image analysis was used to identify cells as S100A8-positive, MPO-positive, or co-labelled. Venn diagram of overlap between
S100A8 and MPO. Human brain tissue microarrays from the middle temporal gyrus (N = 21–28 per condition) were labelled with the vascular
marker lectin and MPO. d Representative images and e quantification of the localisation of MPO within large (> 12 μm diameter) and small (< 12 μm
diameter) lectin-positive vessels. Scale bar = 100 μm. Values represent results of a two-way ANOVA. f Quantification of the percentage of total MPO
load present in blood vessels in AD and control brains. Wild-type or APP/PS1 mouse brains at 4 and 12 months of age were labelled for vascular
marker tomato lectin (LEL) and neutrophil markers (MPO/S100A8). g Representative images of neutrophils associated with BBB leakage product
hemoglobin in AD brains. Scale = 100 μm. h Representative images of MPO and S100A8-positive neutrophils in 12 month-old APP/PS1 vasculature.
Scale bar = 5 mm, inset = 100 μm
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as gallstones and cholesterol crystals, neutrophils may
respond to aggregated forms of Aβ1-42 through NET formation [29, 30]. However, we did not detect NETosis in
response to Aβ1-42 in any aggregation state in vitro (Additional file 1: Fig. S4). Furthermore, we only observed
CitH3 localised to vascular neutrophils (Fig. 4b, f ), but
not plaque associated MPO-deposits as we originally
hypothesised. MPO in these regions was colocalised with
activated microglial markers Iba1, L-ferritin, and HLADR (Fig. 4c). Although NETs were present at higher levels
in AD, they were only present in low abundance and in
less than half of the cohort (Fig. 4d-g).
Reduced endothelial glycocalyx in AD vessels

During previous experiments (Figs. 2, 3, 4), we observed
a reduction in the intensity of staining for UEA1 lectin, a
marker for fucosylation in the glycocalyx, in human AD
vessels. Indeed, image analysis indicated that there was
significantly reduced UEA1 staining intensity in AD, irrespective of vessel size (Fig. 5a, b). To ensure results were
not confounded by changes to vascular density, we used
collagen IV as a total vascular marker, and measured lectin intensity within collagen-positive structures, again
segregating large and small vessels. There was a similar reduction in the lectin staining, particularly in small
vessels, however a similar trend was observed in large
vessels too (Fig. 5a, b). We also interrogated potential
mechanisms through which attachment may be mediated using a single-cell RNAseq atlas of the AD vasculature [40]. Interestingly, although there were no increases
in the expression of cell adhesion molecules (ICAM1,
ICAM2, VCAM1, SELE) in endothelial cells, there was a
decrease in FUT11, an enzyme associated with the production of the glycocalyx (Fig. 5c, d) [40].

Discussion
While increased MPO [11, 18–20] and cerebral neutrophil accumulation [10–13] are well-established features
of AD, there have been several reports of unusual cellular
sources and localisations of MPO. Previous reports have
primarily focussed on the accumulation of neutrophils
in mouse models [10–13], or have used a limited panel
of antibodies [11, 18, 19]. We used tissue from a large
human cohort and mouse tissue to show that MPO deposition in the AD brain is primarily driven by neutrophil
accumulation. The majority of this MPO is contained in
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vascular-associated neutrophils, confirming reports from
animal models of AD [12]. Furthermore, we find evidence
for vascular NETosis in human AD. Finally, we observe
a decrease in staining for the glycocalyx using UEA-1
lectin to indicate that reductions in the endothelial glycocalyx may drive neutrophil accumulation in the AD
vasculature.
Several reports have indicated that MPO may be produced by non-neutrophil cells, including microglia [19],
astrocytes [20], and neurons [19]. Using multiple different antibodies we confirmed that the majority of MPO
staining was confined to neutrophils. It should be noted
that, although S100A8 can be expressed in other cell
types, MPO was also found almost exclusively colocalized with other neutrophil markers including CD66B.
Furthermore the nuclei associated with MPO were polymorphonuclear. We did, however, observe low levels of
MPO in plaque-associated microglia, reinforcing reports
that it may be a microglial activation marker [46]. Since
the bulk of MPO labelling was confined to neutrophils,
we concluded that the increase of MPO in AD is mainly
driven by the accumulation of neutrophils in the brain.
Strikingly, we predominantly observed neutrophils present within lectin-positive blood vessels, and only very
rarely in the parenchyma in both a mouse model of amyloidosis and in human AD.
Our work corroborates findings from mouse AD models in human AD, suggesting that neutrophil plugging
of capillaries leads to blood flow reductions in AD [12,
13]. Importantly, neutrophil plugging of the vasculature
occurred early in this mouse model, and the removal of
neutrophil plugs led to improved cerebral blood flow
and cognition [12, 13]. While our work was performed
on tissue from end-stage disease, this suggests that neutrophil plugging may also be present early in human AD.
The enhanced neutrophil-vascular interactions observed
in AD suggest that either neutrophils or the vasculature
become ‘stickier’. It is also important to note that human
samples are processed differently to those in mouse
studies, with a significant delay between death and perfusion-fixation, and this may influence the numbers of
neutrophils present in the vasculature. Despite this, tissue processing is consistent between human samples,
and so results remain internally consistent.
There have been conflicting reports, some suggesting
that the cell adhesion molecules ICAM1 and VCAM1

(See figure on next page.)
Fig. 3 Non-vascular localisation of MPO in human Alzheimer’s disease. Tissue microarrays of human middle temporal gyrus were stained for
MPO with pTau, amyloid-β, or CD66B. a Representative images of non-vascular MPO localisation associated with pTau tangles, amyloid-β plaques,
and infiltrating CD66B-positive neutrophils. Scale = 25 μm. Quantification of the amount of b extravascular MPO, c MPO-positive plaques, and d
MPO-positive tangles. Values represent results of an two-tailed Student’s T-test. e Percentage of extravascular MPO associated with plaques and
tangles. Correlation of total MPO load in tissue with the load of f plaques and g tangles. Values represent results of a Pearson’s correlation test
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are enhanced in the AD vasculature [11, 47], but more
recent findings indicate that expression of genes involved
in neutrophil attachment are unchanged in human AD
endothelia [40]. Interestingly, although vascular neutrophils were increased in APP/PS1 mice, the degree
of attachment was lower than in AD, suggesting that
although vascular changes are present, they are not
equivalent [40]. Furthermore, we find that UEA-1 lectin
staining of the endothelial glycocalyx is decreased in AD.
Indeed, loss of endothelial glycocalyx in a mouse model
of subcortical vascular dementia was responsible for capillary stalling [48]. Furthermore, hyaluronan, a marker
of glycocalyx damage, was elevated in the cerebrospinal
fluid of AD and vascular dementia patients [49, 50]. Circulating neutrophils have been reported to be more activated in AD [51], and they can also alter the endothelial
glycocalyx [52, 53], so it is possible that these changes to
neutrophil activation state are responsible for glycocalyx
changes and vascular attachment. However, we speculate that glycocalyx thinning may result from reduced
production with reduced expression of FUT11, a gene
involved in glycocalyx production in AD endothelial cells
[40]. This may allow for enhanced neutrophil attachment, even in the absence of strong cell adhesion molecule expression. Furthermore, in the absence of strong
cell adhesion molecule expression, attachment would not
facilitate neutrophil infiltration, and may explain why
neutrophils remain in the vasculature. In human samples
though, it is worth noting that we could not distinguish
the means through which neutrophils had become present in vessels. Indeed, it is possible that the observed
accumulation of neutrophils here may have been the
result of them becoming trapped, rather than adhering the vessel wall. Importantly, although human and
mouse brains were processed differently, we did observe
similar enhancement of vascular associated neutrophils
in AD and the APP/PS1 mouse model of AD indicating
that our observations are unlikely to be the result of a
post-mortem artefact. It will be important to further validate changes to the AD glycocalyx composition, and the
expression of the enzymes that synthesise it. Indeed, it
may be possible to modify endothelial glycocalyx synthesis to prevent neutrophil adhesion to capillaries in AD.
The accumulation of neutrophils and MPO in the
brain vasculature has important consequences for the
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surrounding cells [22]. Indeed, cells at the borders of the
brain can have profound effects on cognition and pathology. MPO binds strongly to the vascular endothelium
through its interactions with the negatively charged glycocalyx in other chronic inflammatory diseases, including heart disease, to cause endothelial dysfunction [52,
54, 55]. Here, too, we observe BBB dysfunction at sites
where neutrophils are attached to blood vessels. Furthermore, MPO impairs the barrier function of brain
endothelial cells through the production of HOCl [56].
HOCl is highly reactive and consumed close to its site of
production [23]. It is possible that longer-lived secondary oxidants such as chloramines mediate the effects of
HOCl on the vasculature [23]. In the presence of thiocyanate concentrations present in plasma, MPO also generates HOSCN [57]. We have found that this longer lived,
thiol-selective oxidant can impact endothelial cells at
sub-lethal doses [58], including disruption of BBB function [59]. In the context of AD, it is possible that neutrophil-vascular interactions are an important mechanism
through which BBB dysfunction is established [22].
We observed very little parenchymal MPO indicating that the majority of neutrophil attachment in AD
does not lead to neutrophil infiltration. However, it is
clear that there is a limited degree of neutrophil infiltration into the AD brain, supporting previous reports [10,
11]. It is interesting to note that we did not observe profound infiltration of neutrophils into the brains of APP/
PS1 mice. While this contradicts results in tauopathy
and 5XFAD mice, it does align with other reports from
the APP/PS1 model, indicating that strain may influence the infiltration of neutrophils in AD models [12].
Furthermore, we detected parenchymal MPO deposits
associated with AD pathology. These MPO deposits were
larger and morphologically different to staining patterns
observed in neutrophils. When activated, neutrophils
are capable of forming NETs, creating a DNA–protein
matrix that has powerful immunostimulatory properties
[28]. We initially hypothesised that these MPO deposits
were NETs however we could not observe colocalisation
of other neutrophil or NET markers. Plaque-associated
MPO deposits were colocalised with markers of activated microglia (HLA-DR, L-ferritin), albeit at much
lower levels than neutrophils. Indeed, MPO may be an
activation marker in microglia in its own right [46]. It is

(See figure on next page.)
Fig. 4 Identification of NETs within blood vessels in human Alzheimer’s disease. AD issue microarrays from the middle temporal gyrus (N = 45–46
per condition) were repeatedly immunostained, imaged, and stripped to build up a multiplexed panel of antibody labelling on the same section.
This panel included the specific marker for NETs CitH3, as well as neutrophil/NET markers MPO and S100A8. a Representative images of all
stains and insets of b NETs and c MPO-positive microglia. Scale bar = 250 μm, inset = 100 μm. d Quantification of the number of CitH3/MPO/
S100A8-positive NETs in AD and control cores. P-values represent results of an two-tailed Student’s T-test. The proportion of e MPO/S100A8-positive
neutrophils positive for CitH3, f localised in blood vessels, and g cases positive for NETs in AD and control
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Fig. 5 Reduction in endothelial glycocalyx in AD brain. AD tissue microarrays from the middle temporal gyrus (N = 21–37 per condition) were
labelled for the total vessel marker collagen IV, and endothelial glycocalyx marker UEA1 lectin. a Representative images of lectin immunolabelling,
and b quantification of lectin intensity in blood vessels in control and AD brains, segregated by vessel size. Scale = 250 μm. P-values represent
results of an two-way ANOVA. Single nuclear RNA-seq from the human AD vasculature were obtained from https://twc-stanford.shinyapps.io/
human_bbb/, and genes involved in c cell adhesion processes, and d fucosylation of the endothelial glycocalyx evaluated
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Fig. 6 Effects of neutrophil-vascular interations in AD. In healthy
brains, neutrophils flow freely through vessels with limited
interactions with endothelial cells enabling adequate perfusion.
During Alzheimer’s disease, reductions in the glycocalyx may
enhance the non-productive attachment of neutrophils to
endothelial cells. These attached neutrophils can cause the stalling
of vessels, undergo NETosis, and may lead to oxidative stress
and blood-brain barrier breakdown. Reducing neutrophil-vascular
interactions may be beneficial to improve vascular function in AD

also possible that parenchymal NETs cannot be detected
through CitH3 labelling, as the citrullination occurs in a
region of the histone tail that is cleaved during NETosis
and is a more robust marker of early, rather than mature,
NETs [60]. Antibodies to NET-specific modifications in
mature NETs could be used to detect this phenomenon
[60].
We observed NETosis in the AD vasculature,
although this was not ubiquitous and the presence of
NETs was rarer than in stroke, our positive control.
There have been other reports of NETosis in sterile neurological diseases, including stroke and traumatic brain
injury, where they are involved in vascular remodelling
[42, 43]. While there are preliminary reports of NETosis in the AD brain [11], their localisation has not been
interrogated. Recent reports indicate that senescent
endothelial cells attract and promote NETosis to trigger
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vascular remodelling in the retina following oxygeninduced retinopathy [44], and that NETs also play a role
in vascular remodelling following stroke [43]. It is possible that a similar phenomenon occurs in AD, leading
to vascular regression [40, 61]. Recent reports suggest
that CNS-associated neutrophils are derived from multiple sources, including the blood and adjacent skull
bone marrow [62, 63]. The vascular association of neutrophils observed here suggests their origin from the
circulation, which may be associated with activated
neutrophil phenotypes in AD that are more prone to
NETosis [62].
The localisation of neutrophils and MPO within cerebral vessels suggests that they may be a peripheral target with the potential to enhance cognitive function in
AD. Indeed, preventing leukocyte tethering to the brain
vasculature improves cognition in aging [64], as well as
in models of AD [11–13]. Furthermore, the presence
of NETs, and therefore extracellular MPO at the brain
vasculature represents a novel AD-associated process.
It may be possible to prevent MPO release by targeting NETosis, degrading NETs, or by addition of molecules that sequester MPO from the glycocalyx to ‘wash’
it off the endothelium without modulating potentially
beneficial functions within the neutrophil cytoplasm
[57,66]. Although the majority of neutrophils in AD
are present at a brain barrier and not within the brain
itself, they may still have important effects on cognition
[9, 11, 12], so targeting inflammation in BBB endothelial cells or through modulation of neutrophils may be a
useful therapeutic target in AD [15].

Conclusions
Here, we confirm data from animal models in the
human AD brain suggesting that neutrophils accumulate, and are associated with blood vessels in AD where
they may contribute to vascular stalling and BBB leakage (Fig. 6). We also show that neutrophils and NETs
are the key source of MPO in the brain during AD
which may represent an important mechanism through
which BBB inflammation influences oxidative stress in
AD.
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